Emergencies preparedness, response

Hepatitis B


1. Churchill's Illustrated Medical Dictionary, New York, Churchill Livingstone, 1989.

2. Abraham P et al. Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Vaccine, 1999, 17:1125-1129.

3. Centers for Disease Control and Prevention. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the immunization practices advisory committee (ACIP). Morbidity and Mortality Weekly Report, 1991, 40:1-19, http://www.cdc.gov/ncidod/diseases/hepatitis/v40rr13.htm.

4. Centers for Disease Control and Prevention. Control measures for hepatitis B in dialysis centers, 1998, http://www.cdc.gov/ncidod/hip/control.htm.

5. Centers for Disease Control and Prevention. Hepatitis B vaccine, 1998, http://www.cdc.gov/ncidod/diseases/hepatitis/b/hebqafn.htm.

6. Chisari FV, Ferrari C. Viral Hepatitis. In: Nathanson N et al., eds. Viral Pathogenesis, Philadelphia, Lippincott - Raven, 1997:745-778.

7. Clemens R et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance. Vaccine, 1997, 15:349-352.

8. Dienstag JL et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology, 1999, 30:1082-1087.

9. Fattovich G et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology, 1999, 26:1338-1342.

10. Ganem D, Schneider RJ. Hepadnaviridae: The Viruses and Their Replication. In: Knipe DM et al., eds. Fields Virology, 4th ed. Philadelphia, Lippincott Williams & Wilkins, 2001:2923-2969.

11. Gitlin N. Hepatitis B: diagnosis, prevention, and treatment. Clinical Chemistry, 1997, 43:1500-1506.

12. Goldwater PN. Randomized, comparative trial of 20 mg vs 40 mg Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine, 1997, 15:353-356.

13. Guidotti LG et al. Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice. Journal of Virology, 1994, 68:5469-5475.

14. Hadziyannis SJ, Manesis EK, Papakonstantinou A. Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study. Journal of Hepatology, 1999, 31:210-214.

15. Hollinger FB, Liang TJ. Hepatitis B Virus. In: Knipe DM et al., eds. Fields Virology, 4th ed. Philadelphia, Lippincott Williams & Wilkins, 2001:2971-3036.

16. Ikeda K et al. Interferon dicreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer, 1998, 82:827-835.

17. Iwarson S. Why the Scandinavian countries have not implemented universal vaccination against hepatitis B. Vaccine, 1998, 16(Suppl):S56-S57.

18. Janssen HL et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. Hepatology, 1999, 30:238-243.

19. Kane MA. Status of hepatitis B immunization programmes in 1998. Vaccine, 1998, 16(Suppl):S104-S108.

20. Lai CL et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. New England Journal of Medicine, 1998, 339:61-68.

21. Lai CL et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology, 1997, 25:241-244.

22. Lau DT et al. Lamivudine for chronic delta hepatitis. Hepatology, 1999, 30:546-549.

23. Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA and Orenstein WA, eds. Vaccines, 3rd ed. Philadelphia, W.B. Saunders Company, 1999:158-182.

24. Markowitz JS et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology, 1998, 28:585-589.

25. Marwick C, Mitka M. Debate revived on hepatitis B vaccine value. JAMA, 1999, 282:15-17.

26. Nevens F et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology, 1997, 113:1258-1263.

27. Niederau C et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. New England Journal of Medicine, 1996, 334:1422-1427.

28. Ogata N et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology, 1999, 30:779-786.

29. Pride MW et al. Evaluation of B and T-cell responses in chimpanzees immunized with Hepagene, a hepatitis B vaccine containing pre-S1, pre-S2 gene products. Vaccine, 1998, 16:543-550.

30. Robinson WS. Hepatitis B viruses. General Features (human). In: Webster RG and Granoff A, eds. Encyclopedia of Virology, London, Academic Press Ltd, 1994:554-569.

31. Robinson WS. Hepatitis B virus and hepatitis D virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 4th ed. New York, Churchill Livingstone, 1995:1406-1439.

32. Tacket CO et al. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine, 1999, 17:2826-2829.

33. Tassopoulos NC et al. Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. Journal of Viral Hepatitis, 1997, 4:387-394.

34. Thoelen S et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine, 1999, 17:1657-1662.

35. Thornton SM, Walker S, and Zuckerman JN. Management of hepatitis B virus infections in two gibbons and a western lowland gorilla in a zoological collection. Veterinary Record, 2001, 149:113-115.

36. Van Damme P, Kane M, and Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. British Medical Journal, 1997, 314:1033-1037.

37. Viral Hepatitis Prevention Board. Antwerp VHPB Report. Editorial. Control of viral hepatitis in Europe. Viral Hepatitis, 1996, 4(2), http://hgins.uia.ac.be/esoc/VHPB/vhv4n2.html.

38. Viral Hepatitis Prevention Board. Prevention and control of hepatitis B in the community. Communicable Disease Series, 1996, 1.

39. Viral Hepatitis Prevention Board. The clock is running,...1997: deadline for integrating hepatitis B vaccinations into all national immunization programmes, 1996 (Fact Sheet VHPB/ 1996/1, http://hgins.uia.ac.be/esoc/VHPB/vhfs1.html).

40. Viral Hepatitis Prevention Board. News from the VHPB meeting in St. Julians, Malta. Viral Hepatitis, 1997, 6, http://hgins.uia.ac.be/esoc/VHPB/maltatxt.html.

41. Viral Hepatitis Prevention Board. Ensuring injection safety and a safe blood supply, 1998 (Fact Sheet VHPB/ 1998/3, http://hgins.uia.ac.be/esoc/VHPB/vhfs3.html).

42. Viral Hepatitis Prevention Board. Universal HB immunization by 1997: where are we now?, 1998 (Fact Sheet VHPB/ 1998/2, http://hgins.uia.ac.be/esoc/VHPB/vhfs2.html).

43. Walton J, Barondess JA, Lock S. The Oxford Medical Companion, Oxford, Oxford University Press, 1994.

44. Wilson JN, Nokes DJ, and Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Vaccine, 1999, 17:973-978.

45. World Health Organization. Laboratory Biosafety Manual, 2nd ed. Geneva, WHO, 1993.

46. World Health Organization. Expanded Programme on Immunization (EPI); Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Weekly Epidemiological Record, 1997, 72:149-152.

47. World Health Organization. Hepatitis B immunization; WHO position. Weekly Epidemiological Record, 1998, 73:329.

48. World Health Organization. No scientific justification to suspend hepatitis B immunization. Geneva, WHO, 1998 (Press Release WHO/67).

49. World Health Organization. Children's vaccines - safety first. Geneva, WHO, 1999 (Note for the press N°18).

50. World Health Organization. Health risks and their avoidance - hepatitis B. In: International travel and health. Vaccination requirements and health advice. Geneva, WHO, 1999:67.

51. World Health Organization. Introduction of hepatitis B vaccine into childhood immunization services.Geneva, WHO, 2001 (unpublished document WHO/V&B/01.31 available on request from Department of Vaccines and Biologicals, World Health Organization, 1211 Geneva 27, Switzerland).

52. Zuckerman AJ. Hepatitis Viruses. In: Baron S, eds. Medical Microbiology, 4th ed. The University of Texas Medical Branch at Galveston, 1996:849-863.

53. Zuckerman AJ. Effect of hepatitis B virus mutants on efficacy of vaccination. Lancet, 2000, 355:1382-1384.